a Study of JY09 in Chinese Healthy Subjects

NCT02971722 · Unknown status

Last updated 2026-05-28

This clinical trial is testing the effects of the investigational drug JY09 on healthy adults in China to understand how it is absorbed and processed by the body.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 26 people Planned (estimated).

Who can join Ages 18–45 · all sexes Healthy volunteers accepted.

Timeline Started 2016-12 · est. completion 2018-03

What this study is testing ClinicalTrials.gov NCT02971722 ↗

Description as written by the study sponsor.

JY09，is a recombinant glucagon-like peptide-1 (GLP-1) receptor agonist,constructed with Exendin-4 and human Immunoglobulin G2 (IgG2) Fc fragment.Preclinical studies show that JY09 exhibit the expected GLP-1-mediated pharmacological effects on insulin secretion,glucose covering and islet cell recovering,as well as good tolerance and safety.JY09 has been approved by China food and drug administration(CFDA) to enter the clinical research stage(Grant number 2016L04254).This study is designed to assess the safety,tolerability,pharmacokinetics,pharmacodynamics and potential immunogenicity of JY09 in healthy Chinese volunteers.

Treatments tested

JY09 Drug

2mg/1ml/bottle
Placebo Drug

1ml/bottle

Main thing measured	Pharmacokinetics (PK)
Sponsor	Beijing Dongfang Biotech Co., Ltd.
Conditions studied	Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02971722 ↗